Keros authorizes $5M buyback after $20M Takeda milestone for elritercept; cash runway to 2H 2028

Keros Therapeutics, Inc.

Board approved $5 million share repurchase program of KROS common stock, announced September 8, 2026.
Program follows $20 million development milestone from Takeda Pharmaceuticals triggered by first patient dose in ELRiSE MDS trial of elritercept.
Repurchases may occur in open market or other means; timing depends on market price and conditions; may be suspended or discontinued.
Cash and equivalents were $257.6 million as of June 30, 2026; funding runway extended into second half of 2028 after milestone and buyback.
Milestone confirms elritercept MDS development progress under license agreement with Takeda.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.